What is it about?
1. The role that the phase-II reaction, glucuronidation, plays in the biotransformation of endo and xenobiotics is discussed with particular emphasis given to the UGT1A1 isoenzyme. This individual isoenzyme is responsible for both the mono and di-glucuronidation of bilirubin together with the glucuronidation of a number of xenobiotics of clinical interest (irinotecan, belinostat, atazanavir, pegvisomant). 2. The review then discusses the roles that the various allelic variants of the UGT1A1 gene play in bilirubin metabolism and in particular how these allelic variants are involved in the clinical manifestation of the diseases of Gilbert’s syndrome;, Crigler-Najjar syndrome 1 and Crigler-Najjar syndrome 2. 3. The review concludes with the roles that the UGT1A1*28 and UGT1A1*6 alleles play in adverse drug reactions (decreased glucuronidation of irinotecan, belinostat, atazanavir, pegvisomant) leading to increased exposure, reduced clearance and neutropenia (irinotecan, belinostat), increased risk for jaundice and hyperbilirubinaemia (atazanavir) and liver toxicity (pegvisomant) before discussing the future role of UGT1A1 in personalised medicine.
Photo by freestocks.org on Unsplash
Why is it important?
An extensive review of the role of UGT1A1 in drug toxicity and disease
Read the Original
This page is a summary of: Uridine diphosphate glucuronosyltransferase 1A1, Xenobiotica, June 2019, Taylor & Francis, DOI: 10.1080/00498254.2019.1617910.
You can read the full text:
Be the first to contribute to this page